John J. Boniface net worth and biography

John Boniface Biography and Net Worth

Chief Scientific Officer of Sera Prognostics

John J. Boniface, Ph.D. has served as our Chief Scientific Officer since November 2011. Prior to that, Dr. Boniface briefly served as our Vice President of Research from September 2011 to November 2011. In his role as Chief Scientific Officer, Dr. Boniface is involved with our product development. Dr. Boniface previously served as scientist and program director for multiple biotechnology companies focused on protein discovery and small molecule and immunotherapeutic drug development, including Myrexis, Myriad Genetics, Prolexys Pharmaceuticals and Eos Biotechnology. Dr. Boniface holds a Ph.D. in Biochemistry from Albany Medical College and a B.S. in Biochemistry from the University of Massachusetts, Amherst. Dr. Boniface was a post-doctoral scholar in the laboratory of Dr. Mark Davis, Department of Microbiology and Immunology, Stanford University School of Medicine.

What is John J. Boniface's net worth?: The estimated net worth of John J. Boniface is at least $301.89 thousand as of March 11th, 2026. Dr. Boniface owns 145,842 shares of Sera Prognostics stock worth more than $301,893 as of September 18th. This net worth estimate does not reflect any other investments that Dr. Boniface may own. Learn More about John J. Boniface's net worth.
How do I contact John J. Boniface?: The corporate mailing address for Dr. Boniface and other Sera Prognostics executives is 2749 E. Parleys Way, Suite 200, Salt Lake City, UT, 84109. Sera Prognostics can also be reached via phone at 801-990-0520 and via email at [email protected]. Learn More on John J. Boniface's contact information.
Has John J. Boniface been buying or selling shares of Sera Prognostics?: John J. Boniface has not been actively trading shares of Sera Prognostics during the last quarter. Most recently, John J. Boniface sold 1,517 shares of the business's stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $2.04, for a transaction totalling $3,094.68. Following the completion of the sale, the insider now directly owns 145,842 shares of the company's stock, valued at $297,517.68. Learn More on John J. Boniface's trading history.
Who are Sera Prognostics' active insiders?: Sera Prognostics' insider roster includes Austin Aerts (Strategic Advisor), John Boniface (Chief Scientific Officer), Benjamin Jackson (General Counsel), Paul Kearney (Data Science Advisor), and Sandra Lawrence (Director). Learn More on Sera Prognostics' active insiders.
Are insiders buying or selling shares of Sera Prognostics?: In the last twelve months, insiders at the sold shares 39 times. They sold a total of 167,112 shares worth more than $394,436.33. The most recent insider tranaction occured on September, 10th when insider Dyaarl Lee Jr. Anderson sold 1,800 shares worth more than $3,600.00. Insiders at Sera Prognostics own 11.3% of the company. Learn More about insider trades at Sera Prognostics.
Information on this page was last updated on 9/10/2026.

John J. Boniface Insider Trading History at Sera Prognostics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2026	Sell	1,517	$2.04	$3,094.68	145,842
3/9/2026	Sell	3,038	$1.96	$5,954.48	147,359
12/10/2025	Sell	1,332	$3.31	$4,408.92	150,397
9/11/2025	Sell	1,395	$3.13	$4,366.35	159,493
6/10/2025	Sell	1,439	$1.48	$2,129.72	167,982
8/7/2024	Sell	5,022	$7.42	$37,263.24	129,847
5/8/2024	Sell	4,902	$9.59	$47,010.18	134,869
3/28/2024	Sell	24,474	$9.04	$221,244.96	139,771
3/26/2024	Sell	21,438	$9.55	$204,732.90	143,524
12/7/2023	Sell	5,000	$4.80	$24,000.00	194,454
7/27/2022	Sell	1,000	$2.22	$2,220.00	46,510
7/19/2022	Sell	2,725	$1.86	$5,068.50	49,235
7/12/2022	Sell	2,725	$1.84	$5,014.00	51,960
7/5/2022	Sell	2,725	$1.63	$4,441.75	54,685
6/29/2022	Sell	1,000	$1.72	$1,720.00	57,410
6/21/2022	Sell	2,725	$1.31	$3,569.75	60,135
6/14/2022	Sell	2,725	$1.21	$3,297.25	62,860
6/7/2022	Sell	2,725	$1.30	$3,542.50	65,585
6/1/2022	Sell	1,000	$1.36	$1,360.00	68,310
5/24/2022	Sell	2,725	$1.54	$4,196.50	71,035
5/17/2022	Sell	2,725	$1.55	$4,223.75	73,760
5/10/2022	Sell	2,725	$1.97	$5,368.25	76,485
5/3/2022	Sell	2,725	$2.17	$5,913.25	79,210
4/26/2022	Sell	2,725	$2.17	$5,913.25	81,935
4/19/2022	Sell	2,725	$2.08	$5,668.00	84,660
4/12/2022	Sell	2,725	$2.66	$7,248.50	87,385
4/6/2022	Sell	1,000	$3.02	$3,020.00	90,110
3/29/2022	Sell	2,725	$3.73	$10,164.25
3/22/2022	Sell	2,725	$3.68	$10,028.00
3/14/2022	Sell	2,725	$3.94	$10,736.50

John J. Boniface Buying and Selling Activity at Sera Prognostics

Sera Prognostics Company Overview

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $2.07

$2.04

$2.08

50 Day Range

MA: $2.05

$1.92

$2.27

2 Week Range

Now: $2.07

$1.56

$3.95

Volume

7,205 shs

Average Volume

23,442 shs

Market Capitalization

$81.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98